Taysha gene therapies announces updates to tsha-102 clinical program in rett syndrome

Reveal adolescent and adult trial will proceed to high dose cohort following independent data monitoring committee approval of company's request to initiate dose escalation; dosing of first patient in cohort two (high dose, n=3) expected in q2 2024
TSHA Ratings Summary
TSHA Quant Ranking